Pioglitazone: A New Paradigm in Management of PCOS; An Open Labelled Study

    July 2020 in “ Zenodo (CERN European Organization for Nuclear Research) ”
    Mohd Ashraf Ganie Aafia Rashid
    From the encyclopedia
    Metformin →

    diabetes drug with anti-inflammatory, immunomodulatory, and insulin-sensitizing properties

    Spironolactone →

    powerful topical and oral anti-androgen used mostly by women

    Studysummary This study found that adding pioglitazone to either spironolactone or metformin improved metabolic parameters and insulin resistance in women with PCOS, despite an increase in BMI.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    This study evaluated the effects of adding pioglitazone to either metformin or spironolactone in 50 women with PCOS over six months. Both treatment groups showed significant improvements in menstrual cycle frequency and Ferriman-Gallwey scores, indicating reduced symptoms of hyperandrogenism. While serum total cholesterol and 2-hour plasma glucose levels showed a nonsignificant decrease, serum total testosterone significantly declined in both groups, with a more pronounced reduction in the pioglitazone and metformin group. Additionally, serum adiponectin levels increased significantly despite an increase in BMI and waist circumference. No major adverse events were reported. The study concluded that pioglitazone, when combined with either metformin or spironolactone, improved metabolic parameters and insulin resistance in women with PCOS, suggesting the need for further randomized trials to confirm these findings.
    Discuss this study in the Community →